A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

January 29, 2024

Study Completion Date

February 12, 2024

Conditions
Primary Sjögren's Syndrome
Interventions
BIOLOGICAL

Efgartigimod

Patients receiving efgartigimod infusions

BIOLOGICAL

Placebo

Patients receiving placebo infusions

Trial Locations (17)

4032

Debreceni Egyetem, Debrecen

8000

Vita Verum Medical Egeszsegugyi Szolgaltato Bt., Székesfehérvár

9000

Universitair Ziekenhuis Gent, Ghent

9713 GZ

Universitair Medisch Centrum Groningen , Dept of Rheumatology and Clinical Immunology, Groningen

82-300

Ambulatorium Barbara Bazela, Elblag

05-825

MCBK Iwona Czajkowska Anna Podrażka- Szczepaniak S.C., Grodzisk Mazowiecki

30-363

Centrum Medyczne Plejady, Krakow

31-501

FutureMeds Krakow, Krakow

20-412

ETG Lublin, Lublin

20-607

Reumed Spolka z o.o., Lublin

60-848

Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k., Poznan

60-185

Centrum Medyczne Pratia Poznan, Skórzewo

00-874

MICS Centrum Medyczne Warszawa, Warsaw

02-637

KO-Med - Centrum Badań Medycznych NIGRiR, Warsaw

02-691

Centrum Medyczne Reuma Park, Warsaw

03-291

FutureMeds Targowek, Warsaw

50-088

FutureMeds Wroclaw, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

argenx

INDUSTRY

NCT05817669 - A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) | Biotech Hunter | Biotech Hunter